CONTEXT: Hematopoietic stem cell transplantation (HSCT) requires significant infrastructure. Little is known about HSCT use and the factors associated with it on a global level. OBJECTIVES: To determine current use of HSCT to assess differences in its application and to explore associations of macroeconomic factors with transplant rates on a global level. DESIGN, SETTING, AND PATIENTS: Retrospective survey study of patients receiving allogeneic and autologous HSCTs for 2006 collected by 1327 centers in 71 participating countries of the Worldwide Network for Blood and Marrow Transplantation. The regional areas used herein are (1) the Americas (the corresponding World Health Organization regions are North and South America); (2) Asia (Southeast Asia and the Western Pacific Region, which includes Australia and New Zealand); (3) Europe (includes Turkey and Israel); and (4) the Eastern Mediterranean and Africa. MAIN OUTCOME MEASURES: Transplant rates (number of HSCTs per 10 million inhabitants) by indication, donor type, and country; description of main differences in HSCT use; and macroeconomic factors of reporting countries associated with HSCT rates. RESULTS: There were 50 417 first HSCTs; 21 516 allogeneic (43%) and 28 901 autologous (57%). The median HSCT rates varied between regions and countries from 48.5 (range, 2.5-505.4) in the Americas, 184 (range, 0.6-488.5) in Asia, 268.9 (range, 5.7-792.1) in Europe, and 47.7 (range, 2.8-95.3) in the Eastern Mediterranean and Africa. No HSCTs were performed in countries with less than 300,000 inhabitants, smaller than 960 km(2), or having less than US $680 gross national income per capita. Use of allogeneic or autologous HSCT, unrelated or family donors for allogeneic HSCT, and proportions of disease indications varied significantly between countries and regions. In linear regression analyses, government health care expenditures (r(2) = 77.33), HSCT team density (indicates the number of transplant teams per 1 million inhabitants; r(2) = 76.28), human development index (r(2) = 74.36), and gross national income per capita (r(2) = 74.04) showed the highest associations with HSCT rates. CONCLUSION: Hematopoietic stem cell transplantation is used for a broad spectrum of indications worldwide, but most frequently in countries with higher gross national incomes, higher governmental health care expenditures, and higher team densities.
CONTEXT: Hematopoietic stem cell transplantation (HSCT) requires significant infrastructure. Little is known about HSCT use and the factors associated with it on a global level. OBJECTIVES: To determine current use of HSCT to assess differences in its application and to explore associations of macroeconomic factors with transplant rates on a global level. DESIGN, SETTING, AND PATIENTS: Retrospective survey study of patients receiving allogeneic and autologous HSCTs for 2006 collected by 1327 centers in 71 participating countries of the Worldwide Network for Blood and Marrow Transplantation. The regional areas used herein are (1) the Americas (the corresponding World Health Organization regions are North and South America); (2) Asia (Southeast Asia and the Western Pacific Region, which includes Australia and New Zealand); (3) Europe (includes Turkey and Israel); and (4) the Eastern Mediterranean and Africa. MAIN OUTCOME MEASURES: Transplant rates (number of HSCTs per 10 million inhabitants) by indication, donor type, and country; description of main differences in HSCT use; and macroeconomic factors of reporting countries associated with HSCT rates. RESULTS: There were 50 417 first HSCTs; 21 516 allogeneic (43%) and 28 901 autologous (57%). The median HSCT rates varied between regions and countries from 48.5 (range, 2.5-505.4) in the Americas, 184 (range, 0.6-488.5) in Asia, 268.9 (range, 5.7-792.1) in Europe, and 47.7 (range, 2.8-95.3) in the Eastern Mediterranean and Africa. No HSCTs were performed in countries with less than 300,000 inhabitants, smaller than 960 km(2), or having less than US $680 gross national income per capita. Use of allogeneic or autologous HSCT, unrelated or family donors for allogeneic HSCT, and proportions of disease indications varied significantly between countries and regions. In linear regression analyses, government health care expenditures (r(2) = 77.33), HSCT team density (indicates the number of transplant teams per 1 million inhabitants; r(2) = 76.28), human development index (r(2) = 74.36), and gross national income per capita (r(2) = 74.04) showed the highest associations with HSCT rates. CONCLUSION: Hematopoietic stem cell transplantation is used for a broad spectrum of indications worldwide, but most frequently in countries with higher gross national incomes, higher governmental health care expenditures, and higher team densities.
Authors: M Hirano; R Martí; C Casali; S Tadesse; T Uldrick; B Fine; D M Escolar; M L Valentino; I Nishino; C Hesdorffer; J Schwartz; R G Hawks; D L Martone; M S Cairo; S DiMauro; M Stanzani; J H Garvin; D G Savage Journal: Neurology Date: 2006-09-13 Impact factor: 9.910
Authors: P Ljungman; A Urbano-Ispizua; M Cavazzana-Calvo; T Demirer; G Dini; H Einsele; A Gratwohl; A Madrigal; D Niederwieser; J Passweg; V Rocha; R Saccardi; H Schouten; N Schmitz; G Socie; A Sureda; J Apperley Journal: Bone Marrow Transplant Date: 2006-03 Impact factor: 5.483
Authors: Ian Nivison-Smith; Kenneth F Bradstock; Anthony J Dodds; Patricia A Hawkins; David D F Ma; John J Moore; Judy M Simpson; Jeff Szer Journal: Biol Blood Marrow Transplant Date: 2007-05-23 Impact factor: 5.742
Authors: Ute Hegenbart; Dietger Niederwieser; Brenda M Sandmaier; Michael B Maris; Judith A Shizuru; Hildegard Greinix; Catherine Cordonnier; Bernard Rio; Alois Gratwohl; Thoralf Lange; Haifa Al-Ali; Barry Storer; David Maloney; Peter McSweeney; Thomas Chauncey; Ed Agura; Benedetto Bruno; Richard T Maziarz; Finn Petersen; Rainer Storb Journal: J Clin Oncol Date: 2005-12-12 Impact factor: 44.544
Authors: Jan J Cornelissen; Wim L J van Putten; Leo F Verdonck; Matthias Theobald; Emanuel Jacky; Simon M G Daenen; Marinus van Marwijk Kooy; Pierre Wijermans; Harry Schouten; Peter C Huijgens; Hans van der Lelie; Martin Fey; Augustin Ferrant; Johan Maertens; Alois Gratwohl; Bob Lowenberg Journal: Blood Date: 2007-01-09 Impact factor: 22.113
Authors: Sebastian Giebel; Myriam Labopin; Adalberto Ibatici; Paul Browne; Tomasz Czerw; Gerard Socie; Ali Unal; Slawomira Kyrcz-Krzemien; Andrea Bacigalupo; Hakan Goker; Mike Potter; Caroline L Furness; Grant McQuaker; Dietrich Beelen; Noel Milpied; Antonio Campos; Charles Craddock; Arnon Nagler; Mohamad Mohty Journal: Oncologist Date: 2016-02-11
Authors: Rania Abasaeed; Susan E Coldwell; Michele E Lloid; Sohaib H Soliman; Paula C Macris; Mark M Schubert Journal: Support Care Cancer Date: 2018-04-27 Impact factor: 3.603
Authors: Raphael Carapito; Ismail Aouadi; Angélique Pichot; Perrine Spinnhirny; Aurore Morlon; Irina Kotova; Cécile Macquin; Véronique Rolli; Anne Cesbron; Katia Gagne; Machteld Oudshoorn; Bronno van der Holt; Myriam Labalette; Eric Spierings; Christophe Picard; Pascale Loiseau; Ryad Tamouza; Antoine Toubert; Anne Parissiadis; Valérie Dubois; Catherine Paillard; Myriam Maumy-Bertrand; Frédéric Bertrand; Peter A von dem Borne; Jürgen H E Kuball; Mauricette Michallet; Bruno Lioure; Régis Peffault de Latour; Didier Blaise; Jan J Cornelissen; Ibrahim Yakoub-Agha; Frans Claas; Philippe Moreau; Dominique Charron; Mohamad Mohty; Yasuo Morishima; Gérard Socié; Seiamak Bahram Journal: Bone Marrow Transplant Date: 2020-04-14 Impact factor: 5.483
Authors: Suzanna M van Walraven; Anneke Brand; Jack N A Bakker; Martin B A Heemskerk; Suzan Nillesen; Marc B Bierings; Laura B Bungener; Bouke G Hepkema; Arjan Lankester; Arnold van der Meer; Kees Sintnicolaas; Judith A E Somers; Eric Spierings; Marcel G J Tilanus; Christien E M Voorter; Jan J Cornelissen; Machteld Oudshoorn Journal: Haematologica Date: 2016-08-25 Impact factor: 9.941